Terms: = Lung cancer AND PRF1, P14222, PFP, P1, MGC65093, HPLH2, FLH2, ENSG00000180644, 5551 AND Clinical Outcome
4 results:
1. GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer.
Bu L; Zhang LB; Mao X; Wang P
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323109
[TBL] [Abstract] [Full Text] [Related]
2. clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
[TBL] [Abstract] [Full Text] [Related]
3. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell lung cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract] [Full Text] [Related]
4. MRP1 and GSTp1 expression in non-small cell lung cancer does not correlate with clinicopathological parameters: A Slovakian population study.
Rybárová S; Hodorová I; Mihalik J; Mirossay L
Acta Histochem; 2014 Oct; 116(8):1390-8. PubMed ID: 25258012
[TBL] [Abstract] [Full Text] [Related]
